KLRC1 and cancer: Importantly, NKG2A blockade has an acceptable safety profile in cancer patients [64] and in mice, anti-NKG2A administration led to partial depletion of HLA-E+ hematopoietic cells, but their numbers recovered 7 days post treatment [68].